[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fK2UiX0HfruF7nnuUSje4_c1G_2rMOSpKIXNa9hg8Kzo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":44,"rows":51},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",[4],99,false,13,6,570534,4,55,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Rheumatoid Arthritis",12,{"name":18,"count":19},"Systemic Lupus Erythematosus",10,{"name":21,"count":9},"Dermatomyositis",{"name":23,"count":24},"Ankylosing Spondylitis",5,{"name":26,"count":24},"Osteoporosis",{"name":28,"count":11},"Osteoarthritis",{"name":30,"count":11},"Polymyositis",{"name":32,"count":11},"Arthritis",[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT01631617","Effects of Treatments on Atopic Dermatitis","2027-01-01","Trimethoprim\u002Fsulfamethoxazole",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05440422","The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD","2027-08-01","anifrolumab",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,97,120,138,156,191,216,240,267,285,310,328,383,427,477,498,525,543,565,590,618,642,660,684,707,731,755,779,805,829,853,876,894,920,938,961,986,1007,1030,1054,1072,1090,1114,1139,1165,1183,1206],{"intervention":53,"totalTrials":54,"cells":55},"Doxycycline",2,{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":75,"PHASE3":91,"PHASE4":93,"NA":95},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[61],{"nctId":62,"briefTitle":63,"status":64,"phases":65,"primaryCompletion":66,"completion":66,"start":67,"enrollment":68,"conditions":69,"interventions":73},"NCT00353158","A Pilot of Pediatric\u002FAdult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity","COMPLETED",[46],"2011-09-20","2007-05-25",62,[70,71,72],"Healthy Volunteers","Fungal Infections","Bacterial Infections",[53,74],"Voriconazole",{"trials":76,"activeCount":90,"soonestReadout":37},[77],{"nctId":35,"briefTitle":36,"status":78,"phases":79,"primaryCompletion":37,"completion":37,"start":80,"enrollment":81,"conditions":82,"interventions":88},"RECRUITING",[47],"2012-09-18",130,[83,84,85,86,87],"Eczema","Dermatitis","Skin Diseases, Genetic","Dermatitis, Atopic","Skin Diseases",[38,89,53],"Cephalexin",1,{"trials":92,"activeCount":58},[],{"trials":94,"activeCount":58},[],{"trials":96,"activeCount":58},[],{"intervention":43,"totalTrials":90,"cells":98},{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":114,"PHASE4":116,"NA":118},{"trials":100,"activeCount":58},[],{"trials":102,"activeCount":58},[],{"trials":104,"activeCount":90,"soonestReadout":42},[105],{"nctId":40,"briefTitle":41,"status":78,"phases":106,"primaryCompletion":42,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":113},[47],"2027-08-02","2023-12-07",45,[18,111,112],"Cardiovascular Disease","Premature Atherosclerosis",[43],{"trials":115,"activeCount":58},[],{"trials":117,"activeCount":58},[],{"trials":119,"activeCount":58},[],{"intervention":38,"totalTrials":90,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":132,"PHASE4":134,"NA":136},{"trials":123,"activeCount":58},[],{"trials":125,"activeCount":58},[],{"trials":127,"activeCount":90,"soonestReadout":37},[128],{"nctId":35,"briefTitle":36,"status":78,"phases":129,"primaryCompletion":37,"completion":37,"start":80,"enrollment":81,"conditions":130,"interventions":131},[47],[83,84,85,86,87],[38,89,53],{"trials":133,"activeCount":58},[],{"trials":135,"activeCount":58},[],{"trials":137,"activeCount":58},[],{"intervention":89,"totalTrials":90,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":141,"activeCount":58},[],{"trials":143,"activeCount":58},[],{"trials":145,"activeCount":90,"soonestReadout":37},[146],{"nctId":35,"briefTitle":36,"status":78,"phases":147,"primaryCompletion":37,"completion":37,"start":80,"enrollment":81,"conditions":148,"interventions":149},[47],[83,84,85,86,87],[38,89,53],{"trials":151,"activeCount":58},[],{"trials":153,"activeCount":58},[],{"trials":155,"activeCount":58},[],{"intervention":157,"totalTrials":54,"cells":158},"Etanercept",{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":175,"PHASE4":187,"NA":189},{"trials":160,"activeCount":58},[],{"trials":162,"activeCount":58},[],{"trials":164,"activeCount":58},[165],{"nctId":166,"briefTitle":167,"status":64,"phases":168,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":174},"NCT00034060","The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept",[47],"2005-12","2002-04",36,[15,173],"Healthy",[157],{"trials":176,"activeCount":58},[177],{"nctId":178,"briefTitle":179,"status":64,"phases":180,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NCT00005007","Etanercept for Wegener's Granulomatosis",[47,48],"2003-03","2000-06",181,[185],"Wegener's Granulomatosis",[157],{"trials":188,"activeCount":58},[],{"trials":190,"activeCount":58},[],{"intervention":192,"totalTrials":90,"cells":193},"High-dose immunoablative therapy",{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":212,"NA":214},{"trials":195,"activeCount":58},[],{"trials":197,"activeCount":58},[],{"trials":199,"activeCount":58},[],{"trials":201,"activeCount":58},[202],{"nctId":203,"briefTitle":204,"status":64,"phases":205,"primaryCompletion":206,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},"NCT00005778","High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide",[48],"2006-04","2000-01",100,[210],"Lupus Erythematosus, Systemic",[192],{"trials":213,"activeCount":58},[],{"trials":215,"activeCount":58},[],{"intervention":217,"totalTrials":90,"cells":218},"gabapentin",{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":236,"NA":238},{"trials":220,"activeCount":58},[],{"trials":222,"activeCount":58},[],{"trials":224,"activeCount":58},[],{"trials":226,"activeCount":58},[227],{"nctId":228,"briefTitle":229,"status":64,"phases":230,"completion":231,"start":181,"enrollment":232,"conditions":233,"interventions":235},"NCT00057278","Gabapentin in Fibromyalgia Trial (GIFT)",[47,48],"2006-01",150,[234],"Fibromyalgia",[217],{"trials":237,"activeCount":58},[],{"trials":239,"activeCount":58},[],{"intervention":241,"totalTrials":90,"cells":242},"Alendronate",{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":263,"NA":265},{"trials":244,"activeCount":58},[],{"trials":246,"activeCount":58},[],{"trials":248,"activeCount":58},[],{"trials":250,"activeCount":58},[251],{"nctId":252,"briefTitle":253,"status":254,"phases":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT00000430","Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis","TERMINATED",[48],"2004-09","1999-10",240,[260,26],"Osteopenia",[241,262],"Estrogen\u002Fprogestin therapy",{"trials":264,"activeCount":58},[],{"trials":266,"activeCount":58},[],{"intervention":262,"totalTrials":90,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":281,"NA":283},{"trials":270,"activeCount":58},[],{"trials":272,"activeCount":58},[],{"trials":274,"activeCount":58},[],{"trials":276,"activeCount":58},[277],{"nctId":252,"briefTitle":253,"status":254,"phases":278,"completion":256,"start":257,"enrollment":258,"conditions":279,"interventions":280},[48],[260,26],[241,262],{"trials":282,"activeCount":58},[],{"trials":284,"activeCount":58},[],{"intervention":286,"totalTrials":90,"cells":287},"Nitroglycerin ointment",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":306,"NA":308},{"trials":289,"activeCount":58},[],{"trials":291,"activeCount":58},[],{"trials":293,"activeCount":58},[],{"trials":295,"activeCount":58},[296],{"nctId":297,"briefTitle":298,"status":64,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":304},"NCT00043719","Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal Women",[48],"2007-12","2002-07",200,[26,260],[286,305],"Calcium supplement with vitamin D",{"trials":307,"activeCount":58},[],{"trials":309,"activeCount":58},[],{"intervention":305,"totalTrials":90,"cells":311},{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":318,"PHASE4":324,"NA":326},{"trials":313,"activeCount":58},[],{"trials":315,"activeCount":58},[],{"trials":317,"activeCount":58},[],{"trials":319,"activeCount":58},[320],{"nctId":297,"briefTitle":298,"status":64,"phases":321,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":322,"interventions":323},[48],[26,260],[286,305],{"trials":325,"activeCount":58},[],{"trials":327,"activeCount":58},[],{"intervention":329,"totalTrials":330,"cells":331},"Anakinra",3,{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":377,"PHASE4":379,"NA":381},{"trials":333,"activeCount":58},[],{"trials":335,"activeCount":58},[],{"trials":337,"activeCount":58},[338,352,366],{"nctId":339,"briefTitle":340,"status":64,"phases":341,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":351},"NCT01794117","Anakinra for Inflammatory Pustular Skin Diseases",[47],"2019-03-19","2019-10-07","2013-07-22",18,[347,348,349,350],"Sneddon-Wilkinson","Acrodermatitis Continua of Hallopeau","Pustular Psoriasis","Palmoplantar Pustulosis",[329],{"nctId":353,"briefTitle":354,"status":254,"phases":355,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":364},"NCT00069329","Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease",[46,47],"2010-04","2003-09",43,[360,361,362,363],"Nervous System Malformations","Arthropathy, Neurogenic","Urticaria","Papilledema",[365],"anakinra",{"nctId":367,"briefTitle":368,"status":64,"phases":369,"primaryCompletion":370,"completion":371,"start":372,"enrollment":9,"conditions":373,"interventions":376},"NCT01441076","Anakinra for Behcet s Disease",[46,47],"2014-10","2014-11","2011-09",[374,375],"Autoimmune Connective Tissue Disorder","Immune System Diseases",[329],{"trials":378,"activeCount":58},[],{"trials":380,"activeCount":58},[],{"trials":382,"activeCount":58},[],{"intervention":384,"totalTrials":330,"cells":385},"Infliximab",{"EARLY_PHASE1":386,"PHASE1":388,"PHASE2":390,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":387,"activeCount":58},[],{"trials":389,"activeCount":58},[],{"trials":391,"activeCount":58},[392,402,411],{"nctId":393,"briefTitle":394,"status":254,"phases":395,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":401},"NCT00029042","Infliximab to Treat Children With Juvenile Rheumatoid Arthritis",[47],"2005-10","2002-01",48,[400],"Juvenile Rheumatoid Arthritis",[384],{"nctId":403,"briefTitle":404,"status":64,"phases":405,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":410},"NCT00006292","Infliximab for the Treatment of Early Rheumatoid Arthritis",[47],"2005-09","2000-09",60,[15],[384],{"nctId":412,"briefTitle":413,"status":64,"phases":414,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":420},"NCT00033891","Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis",[47],"2007-07-31","2010-05-20","2002-04-10",14,[21,30],[384],{"trials":422,"activeCount":58},[],{"trials":424,"activeCount":58},[],{"trials":426,"activeCount":58},[],{"intervention":428,"totalTrials":330,"cells":429},"Fludarabine",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":446,"PHASE3":471,"PHASE4":473,"NA":475},{"trials":431,"activeCount":58},[],{"trials":433,"activeCount":58},[434],{"nctId":435,"briefTitle":436,"status":254,"phases":437,"primaryCompletion":438,"completion":438,"start":301,"enrollment":439,"conditions":440,"interventions":443},"NCT00040651","Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients",[46],"2007-03",15,[441,442],"Scleroderma","Systemic Sclerosis",[428,444,445],"Cyclophosphamide","Thymoglobulin",{"trials":447,"activeCount":58},[448,460],{"nctId":449,"briefTitle":450,"status":64,"phases":451,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":458},"NCT00001422","A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis",[47],"2000-04","1995-06",20,[456,457],"Arthritis, Psoriatic","Psoriasis",[459],"fludarabine",{"nctId":461,"briefTitle":462,"status":64,"phases":463,"completion":452,"start":464,"enrollment":465,"conditions":466,"interventions":469},"NCT00001677","Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy",[47],"1998-06",40,[467,468],"Arthritis, Rheumatoid","Synovitis",[470,428],"Methotrexate",{"trials":472,"activeCount":58},[],{"trials":474,"activeCount":58},[],{"trials":476,"activeCount":58},[],{"intervention":478,"totalTrials":90,"cells":479},"Pamidronate",{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":492,"PHASE4":494,"NA":496},{"trials":481,"activeCount":58},[],{"trials":483,"activeCount":58},[],{"trials":485,"activeCount":58},[486],{"nctId":487,"briefTitle":488,"status":254,"phases":489,"completion":406,"enrollment":465,"conditions":490,"interventions":491},"NCT00022841","Prevention of Steroid-Induced Osteoporosis in Children",[46,47],[26],[478],{"trials":493,"activeCount":58},[],{"trials":495,"activeCount":58},[],{"trials":497,"activeCount":58},[],{"intervention":499,"totalTrials":90,"cells":500},"Ruxolitinib 1.5% cream",{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":502,"activeCount":58},[],{"trials":504,"activeCount":58},[],{"trials":506,"activeCount":58},[507],{"nctId":508,"briefTitle":509,"status":254,"phases":510,"primaryCompletion":511,"completion":511,"start":512,"enrollment":90,"conditions":513,"interventions":517},"NCT03395340","Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)",[47],"2019-01-31","2018-11-19",[514,515,516],"Graft Versus Host Disease","JNS Kinase","Topical Administration",[499,518],"vehicle cream",{"trials":520,"activeCount":58},[],{"trials":522,"activeCount":58},[],{"trials":524,"activeCount":58},[],{"intervention":518,"totalTrials":90,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":528,"activeCount":58},[],{"trials":530,"activeCount":58},[],{"trials":532,"activeCount":58},[533],{"nctId":508,"briefTitle":509,"status":254,"phases":534,"primaryCompletion":511,"completion":511,"start":512,"enrollment":90,"conditions":535,"interventions":536},[47],[514,515,516],[499,518],{"trials":538,"activeCount":58},[],{"trials":540,"activeCount":58},[],{"trials":542,"activeCount":58},[],{"intervention":544,"totalTrials":90,"cells":545},"methimazole",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":559,"PHASE4":561,"NA":563},{"trials":547,"activeCount":58},[],{"trials":549,"activeCount":58},[],{"trials":551,"activeCount":58},[552],{"nctId":553,"briefTitle":554,"status":64,"phases":555,"completion":556,"start":453,"enrollment":454,"conditions":557,"interventions":558},"NCT00001421","Methimazole to Treat Polymyositis and Dermatomyositis",[47],"2001-04",[21,30],[544],{"trials":560,"activeCount":58},[],{"trials":562,"activeCount":58},[],{"trials":564,"activeCount":58},[],{"intervention":566,"totalTrials":90,"cells":567},"BG9588",{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":584,"PHASE4":586,"NA":588},{"trials":569,"activeCount":58},[],{"trials":571,"activeCount":58},[],{"trials":573,"activeCount":58},[574],{"nctId":575,"briefTitle":576,"status":64,"phases":577,"completion":578,"start":579,"enrollment":454,"conditions":580,"interventions":583},"NCT00001789","BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis",[47],"2000-05","1999-06",[581,582],"Glomerulonephritis, Membranoproliferative","Lupus Nephritis",[566],{"trials":585,"activeCount":58},[],{"trials":587,"activeCount":58},[],{"trials":589,"activeCount":58},[],{"intervention":591,"totalTrials":90,"cells":592},"IL-1 Trap",{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":612,"PHASE4":614,"NA":616},{"trials":594,"activeCount":58},[],{"trials":596,"activeCount":58},[],{"trials":598,"activeCount":58},[599],{"nctId":600,"briefTitle":601,"status":64,"phases":602,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":611},"NCT00094900","Interleukin-1 Trap to Treat Autoinflammatory Diseases",[47],"2010-09","2010-12","2004-10",11,[608,609,610],"Inflammation","Familial Mediterranean Fever","Still's Disease, Adult-Onset",[591],{"trials":613,"activeCount":58},[],{"trials":615,"activeCount":58},[],{"trials":617,"activeCount":58},[],{"intervention":619,"totalTrials":90,"cells":620},"dnaJ peptide",{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":622,"activeCount":58},[],{"trials":624,"activeCount":58},[],{"trials":626,"activeCount":58},[627],{"nctId":628,"briefTitle":629,"status":64,"phases":630,"completion":256,"start":631,"enrollment":632,"conditions":633,"interventions":634},"NCT00000435","dnaJ Peptide for Relieving Rheumatoid Arthritis",[47],"1999-09",160,[15],[619,635],"None-placebo",{"trials":637,"activeCount":58},[],{"trials":639,"activeCount":58},[],{"trials":641,"activeCount":58},[],{"intervention":635,"totalTrials":90,"cells":643},{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":648,"PHASE3":654,"PHASE4":656,"NA":658},{"trials":645,"activeCount":58},[],{"trials":647,"activeCount":58},[],{"trials":649,"activeCount":58},[650],{"nctId":628,"briefTitle":629,"status":64,"phases":651,"completion":256,"start":631,"enrollment":632,"conditions":652,"interventions":653},[47],[15],[619,635],{"trials":655,"activeCount":58},[],{"trials":657,"activeCount":58},[],{"trials":659,"activeCount":58},[],{"intervention":661,"totalTrials":90,"cells":662},"Anti-Tumor Necrosis Factor",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":664,"activeCount":58},[],{"trials":666,"activeCount":58},[],{"trials":668,"activeCount":58},[669],{"nctId":670,"briefTitle":671,"status":64,"phases":672,"completion":673,"start":257,"enrollment":674,"conditions":675,"interventions":677},"NCT00000433","Blocking Tumor Necrosis Factor in Ankylosing Spondylitis",[47],"2002-03",42,[676],"Spondylitis, Ankylosing",[661],{"trials":679,"activeCount":58},[],{"trials":681,"activeCount":58},[],{"trials":683,"activeCount":58},[],{"intervention":685,"totalTrials":90,"cells":686},"h5G1.1-mAb",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":701,"PHASE4":703,"NA":705},{"trials":688,"activeCount":58},[],{"trials":690,"activeCount":58},[],{"trials":692,"activeCount":58},[693],{"nctId":694,"briefTitle":695,"status":64,"phases":696,"completion":697,"start":452,"enrollment":698,"conditions":699,"interventions":700},"NCT00005571","Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis",[47],"2001-12",17,[21],[685],{"trials":702,"activeCount":58},[],{"trials":704,"activeCount":58},[],{"trials":706,"activeCount":58},[],{"intervention":708,"totalTrials":90,"cells":709},"Pioglitazone",{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":711,"activeCount":58},[],{"trials":713,"activeCount":58},[],{"trials":715,"activeCount":58},[716],{"nctId":717,"briefTitle":718,"status":64,"phases":719,"primaryCompletion":720,"completion":720,"start":721,"enrollment":722,"conditions":723,"interventions":724},"NCT02338999","Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)",[46,47],"2020-07-14","2015-06-18",88,[18],[708],{"trials":726,"activeCount":58},[],{"trials":728,"activeCount":58},[],{"trials":730,"activeCount":58},[],{"intervention":732,"totalTrials":90,"cells":733},"Rilonacept",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":749,"PHASE4":751,"NA":753},{"trials":735,"activeCount":58},[],{"trials":737,"activeCount":58},[],{"trials":739,"activeCount":58},[740],{"nctId":741,"briefTitle":742,"status":64,"phases":743,"primaryCompletion":744,"completion":744,"start":745,"enrollment":9,"conditions":746,"interventions":748},"NCT01801449","Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)",[47],"2016-04-28","2013-02-12",[747],"DIRA",[732],{"trials":750,"activeCount":58},[],{"trials":752,"activeCount":58},[],{"trials":754,"activeCount":58},[],{"intervention":756,"totalTrials":90,"cells":757},"Oral bovine type I collagen",{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":773,"PHASE4":775,"NA":777},{"trials":759,"activeCount":58},[],{"trials":761,"activeCount":58},[],{"trials":763,"activeCount":58},[764],{"nctId":765,"briefTitle":766,"status":64,"phases":767,"primaryCompletion":768,"start":452,"enrollment":769,"conditions":770,"interventions":772},"NCT00005675","Oral Type I Collagen for Relieving Scleroderma",[47],"2005-05",168,[441,771],"Connective Tissue Diseases",[756],{"trials":774,"activeCount":58},[],{"trials":776,"activeCount":58},[],{"trials":778,"activeCount":58},[],{"intervention":780,"totalTrials":90,"cells":781},"Abatacept",{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":799,"PHASE4":801,"NA":803},{"trials":783,"activeCount":58},[],{"trials":785,"activeCount":58},[],{"trials":787,"activeCount":58},[788],{"nctId":789,"briefTitle":790,"status":64,"phases":791,"primaryCompletion":792,"completion":792,"start":793,"enrollment":794,"conditions":795,"interventions":798},"NCT00556439","Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis",[47],"2015-08","2008-12",97,[796,797],"Takayasu's Arteritis","Giant Cell Arteritis",[780],{"trials":800,"activeCount":58},[],{"trials":802,"activeCount":58},[],{"trials":804,"activeCount":58},[],{"intervention":806,"totalTrials":90,"cells":807},"Deucravacitinb",{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":809,"activeCount":58},[],{"trials":811,"activeCount":58},[],{"trials":813,"activeCount":58},[814],{"nctId":815,"briefTitle":816,"status":817,"phases":818,"primaryCompletion":819,"completion":819,"start":819,"enrollment":58,"conditions":820,"interventions":822},"NCT07012057","Study of Deucravacitinib for Refractory Adults With Dermatomyositis\u002FJuvenile Dermatomyositis","WITHDRAWN",[47],"2025-11-21",[821,21],"Myositis",[806],{"trials":824,"activeCount":58},[],{"trials":826,"activeCount":58},[],{"trials":828,"activeCount":58},[],{"intervention":830,"totalTrials":90,"cells":831},"TwHF",{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":833,"activeCount":58},[],{"trials":835,"activeCount":58},[],{"trials":837,"activeCount":58},[838],{"nctId":839,"briefTitle":840,"status":64,"phases":841,"completion":842,"start":843,"enrollment":844,"conditions":845,"interventions":846},"NCT00062465","Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine",[47],"2006-03","2003-06",157,[15],[830],{"trials":848,"activeCount":58},[],{"trials":850,"activeCount":58},[],{"trials":852,"activeCount":58},[],{"intervention":854,"totalTrials":90,"cells":855},"Parathyroid hormone ointment",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":870,"PHASE4":872,"NA":874},{"trials":857,"activeCount":58},[],{"trials":859,"activeCount":58},[],{"trials":861,"activeCount":58},[862],{"nctId":863,"briefTitle":864,"status":64,"phases":865,"completion":866,"start":207,"enrollment":465,"conditions":867,"interventions":869},"NCT00007306","Treatment of Psoriasis With Parathyroid Hormone",[46,47],"2005-04",[868],"Plaque Psoriasis",[854],{"trials":871,"activeCount":58},[],{"trials":873,"activeCount":58},[],{"trials":875,"activeCount":58},[],{"intervention":470,"totalTrials":90,"cells":877},{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":888,"PHASE4":890,"NA":892},{"trials":879,"activeCount":58},[],{"trials":881,"activeCount":58},[],{"trials":883,"activeCount":58},[884],{"nctId":461,"briefTitle":462,"status":64,"phases":885,"completion":452,"start":464,"enrollment":465,"conditions":886,"interventions":887},[47],[467,468],[470,428],{"trials":889,"activeCount":58},[],{"trials":891,"activeCount":58},[],{"trials":893,"activeCount":58},[],{"intervention":895,"totalTrials":90,"cells":896},"XOMA 052",{"EARLY_PHASE1":897,"PHASE1":899,"PHASE2":901,"PHASE3":914,"PHASE4":916,"NA":918},{"trials":898,"activeCount":58},[],{"trials":900,"activeCount":58},[],{"trials":902,"activeCount":58},[903],{"nctId":904,"briefTitle":905,"status":817,"phases":906,"primaryCompletion":907,"completion":907,"start":908,"enrollment":58,"conditions":909,"interventions":913},"NCT01211977","A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome \u002F Muckle-Wells Syndrome and Behcet's Disease",[46,47],"2011-04-29","2010-08-27",[910,911,912],"Muckle Wells Syndrome","Autoinflammatory","Behcet's Disease",[895],{"trials":915,"activeCount":58},[],{"trials":917,"activeCount":58},[],{"trials":919,"activeCount":58},[],{"intervention":74,"totalTrials":90,"cells":921},{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":930,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":923,"activeCount":58},[],{"trials":925,"activeCount":58},[926],{"nctId":62,"briefTitle":63,"status":64,"phases":927,"primaryCompletion":66,"completion":66,"start":67,"enrollment":68,"conditions":928,"interventions":929},[46],[70,71,72],[53,74],{"trials":931,"activeCount":58},[],{"trials":933,"activeCount":58},[],{"trials":935,"activeCount":58},[],{"trials":937,"activeCount":58},[],{"intervention":939,"totalTrials":90,"cells":940},"Gusacitinib",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":942,"activeCount":58},[],{"trials":944,"activeCount":58},[945],{"nctId":946,"briefTitle":947,"status":817,"phases":948,"primaryCompletion":949,"completion":950,"start":949,"enrollment":58,"conditions":951,"interventions":952},"NCT06238531","A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus",[46],"2025-01-22","2025-01-23",[18],[939],{"trials":954,"activeCount":58},[],{"trials":956,"activeCount":58},[],{"trials":958,"activeCount":58},[],{"trials":960,"activeCount":58},[],{"intervention":962,"totalTrials":90,"cells":963},"MRA 003 US",{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":978,"PHASE3":980,"PHASE4":982,"NA":984},{"trials":965,"activeCount":58},[],{"trials":967,"activeCount":58},[968],{"nctId":969,"briefTitle":970,"status":64,"phases":971,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":977},"NCT00046774","Monoclonal Antibody Treatment for Systemic Lupus Erythematosus",[46],"2007-01-01","2017-09-07","2002-09-02",23,[18],[962],{"trials":979,"activeCount":58},[],{"trials":981,"activeCount":58},[],{"trials":983,"activeCount":58},[],{"trials":985,"activeCount":58},[],{"intervention":987,"totalTrials":90,"cells":988},"15-O labeled water",{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1005},{"trials":990,"activeCount":58},[],{"trials":992,"activeCount":58},[993],{"nctId":994,"briefTitle":995,"status":64,"phases":996,"completion":181,"start":556,"enrollment":19,"conditions":997,"interventions":998},"NCT00014794","Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate Synovial Blood Flow in Rheumatoid Arthritis Patients",[46],[15],[987],{"trials":1000,"activeCount":58},[],{"trials":1002,"activeCount":58},[],{"trials":1004,"activeCount":58},[],{"trials":1006,"activeCount":58},[],{"intervention":1008,"totalTrials":90,"cells":1009},"hLL2",{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1022,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1011,"activeCount":58},[],{"trials":1013,"activeCount":58},[1014],{"nctId":1015,"briefTitle":1016,"status":64,"phases":1017,"completion":1018,"start":1019,"enrollment":454,"conditions":1020,"interventions":1021},"NCT00011908","Humanized LL2IGG to Treat Systemic Lupus Erythematosus",[46],"2003-01","2001-02",[18],[1008],{"trials":1023,"activeCount":58},[],{"trials":1025,"activeCount":58},[],{"trials":1027,"activeCount":58},[],{"trials":1029,"activeCount":58},[],{"intervention":1031,"totalTrials":90,"cells":1032},"SQ Fludarabine",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1046,"PHASE3":1048,"PHASE4":1050,"NA":1052},{"trials":1034,"activeCount":58},[],{"trials":1036,"activeCount":58},[1037],{"nctId":1038,"briefTitle":1039,"status":64,"phases":1040,"completion":1041,"start":1042,"enrollment":439,"conditions":1043,"interventions":1045},"NCT00001676","Cyclophosphamide and Fludarabine to Treat Lupus Nephritis",[46],"2002-11","1998-01",[1044,582,18],"Glomerulonephritis",[1031],{"trials":1047,"activeCount":58},[],{"trials":1049,"activeCount":58},[],{"trials":1051,"activeCount":58},[],{"trials":1053,"activeCount":58},[],{"intervention":444,"totalTrials":90,"cells":1055},{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1064,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1057,"activeCount":58},[],{"trials":1059,"activeCount":58},[1060],{"nctId":435,"briefTitle":436,"status":254,"phases":1061,"primaryCompletion":438,"completion":438,"start":301,"enrollment":439,"conditions":1062,"interventions":1063},[46],[441,442],[428,444,445],{"trials":1065,"activeCount":58},[],{"trials":1067,"activeCount":58},[],{"trials":1069,"activeCount":58},[],{"trials":1071,"activeCount":58},[],{"intervention":445,"totalTrials":90,"cells":1073},{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1082,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1075,"activeCount":58},[],{"trials":1077,"activeCount":58},[1078],{"nctId":435,"briefTitle":436,"status":254,"phases":1079,"primaryCompletion":438,"completion":438,"start":301,"enrollment":439,"conditions":1080,"interventions":1081},[46],[441,442],[428,444,445],{"trials":1083,"activeCount":58},[],{"trials":1085,"activeCount":58},[],{"trials":1087,"activeCount":58},[],{"trials":1089,"activeCount":58},[],{"intervention":1091,"totalTrials":90,"cells":1092},"Tofacitinib",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1106,"PHASE3":1108,"PHASE4":1110,"NA":1112},{"trials":1094,"activeCount":58},[],{"trials":1096,"activeCount":58},[1097],{"nctId":1098,"briefTitle":1099,"status":64,"phases":1100,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":1104,"interventions":1105},"NCT02535689","Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus",[46],"2018-04-26","2015-08-28",34,[18],[1091],{"trials":1107,"activeCount":58},[],{"trials":1109,"activeCount":58},[],{"trials":1111,"activeCount":58},[],{"trials":1113,"activeCount":58},[],{"intervention":1115,"totalTrials":90,"cells":1116},"Omalizumab",{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1131,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1118,"activeCount":58},[],{"trials":1120,"activeCount":58},[1121],{"nctId":1122,"briefTitle":1123,"status":64,"phases":1124,"primaryCompletion":1125,"completion":1125,"start":1126,"enrollment":698,"conditions":1127,"interventions":1130},"NCT01716312","Omalizumab for Lupus",[46],"2017-08-24","2014-01-08",[1128,1129],"Systemic Lupus Erthematosus","Sjogren's Syndrome",[1115],{"trials":1132,"activeCount":58},[],{"trials":1134,"activeCount":58},[],{"trials":1136,"activeCount":58},[],{"trials":1138,"activeCount":58},[],{"intervention":1140,"totalTrials":90,"cells":1141},"Solu-Medrol 1mg\u002Fkg",{"EARLY_PHASE1":1142,"PHASE1":1155,"PHASE2":1157,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1143,"activeCount":58},[1144],{"nctId":1145,"briefTitle":1146,"status":64,"phases":1147,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1153},"NCT04233164","Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus",[45],"2022-05-03","2020-03-04",47,[1152],"Systemic Lupus Erythematous (SLE)",[1140,1154],"Solu-Medrol 250 mg",{"trials":1156,"activeCount":58},[],{"trials":1158,"activeCount":58},[],{"trials":1160,"activeCount":58},[],{"trials":1162,"activeCount":58},[],{"trials":1164,"activeCount":58},[],{"intervention":1154,"totalTrials":90,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1173,"PHASE2":1175,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1168,"activeCount":58},[1169],{"nctId":1145,"briefTitle":1146,"status":64,"phases":1170,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":1171,"interventions":1172},[45],[1152],[1140,1154],{"trials":1174,"activeCount":58},[],{"trials":1176,"activeCount":58},[],{"trials":1178,"activeCount":58},[],{"trials":1180,"activeCount":58},[],{"trials":1182,"activeCount":58},[],{"intervention":1184,"totalTrials":90,"cells":1185},"2-deoxy-2 [F-18] fluoro-2-d-glucose",{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1192,"PHASE4":1194,"NA":1196},{"trials":1187,"activeCount":58},[],{"trials":1189,"activeCount":58},[],{"trials":1191,"activeCount":58},[],{"trials":1193,"activeCount":58},[],{"trials":1195,"activeCount":58},[],{"trials":1197,"activeCount":58},[1198],{"nctId":1199,"briefTitle":1200,"status":64,"phases":1201,"completion":1041,"start":397,"enrollment":454,"conditions":1202,"interventions":1205},"NCT00029926","Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity",[],[1203,1204],"Lupus Erythematosus","Systemic",[1184],{"intervention":1207,"totalTrials":90,"cells":1208},"isotretinoin",{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1215,"PHASE4":1217,"NA":1219},{"trials":1210,"activeCount":58},[],{"trials":1212,"activeCount":58},[],{"trials":1214,"activeCount":58},[],{"trials":1216,"activeCount":58},[],{"trials":1218,"activeCount":58},[],{"trials":1220,"activeCount":58},[1221],{"nctId":1222,"briefTitle":1223,"status":64,"phases":1224,"completion":1225,"start":1226,"conditions":1227,"interventions":1230},"NCT00025012","Isotretinoin in Preventing Skin Cancer",[50],"2004-02","1991-06",[1228,1229],"Melanoma (Skin)","Non-melanomatous Skin Cancer",[1207]]